ArticleJournal of the National Cancer Institute2025
Extended endocrine therapy use and decision making after breast cancer diagnosis.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Patient-reported duplication and missed breast cancer survivorship care more than 5 years after initial treatment.Journal of cancer survivorship : research and practice · 2026Article
- Integrating machine learning and clinicopathological data to stratify survival risk in young women with localized breast cancer.Frontiers in medicine · 2026Article
- Women's Insights on Extended Adjuvant Endocrine Therapy for Breast Cancer: Qualitative Online Forums Study.Journal of medical Internet research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAdjuvant endocrine therapy is recommended to extend beyond 5 years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision making about extended endocrine therapy.
methodsWomen aged 20-79 years diagnosed with stage I-II breast cancer in 2014-2015 and reported to Georgia and Los Angeles County Surveillance, Epidemiology, and End Results registries were surveyed at 7 months and again at 6 years postdiagnosis (n = 2361; response rate = 60%). Women with estrogen receptor-positive and/or progesterone receptor-positive disease were asked about their decision whether to continue therapy.
resultsOf 831 women, 591 had completed or were completing 5 years of endocrine therapy. Among those who had decided (n = 557), 46.9% decided to continue (39.4% stage I; 62.4% stage II). On multivariable analysis, factors associated with continuation for stage I were as follows: worry about recurrence (adjusted odds ratio [aOR] = 3.35, 95% confidence interval [CI] = 1.78 to 6.32), desire for most extensive treatment (aOR = 2.15, 95% CI = 1.1 to 4.14), and primary care physician participation (aOR = 4.30, 95% CI = 2.22 to 8.32). Side effects were inversely associated with continuation (stage I: aOR = 0.21, 95% CI = 0.11 to 0.41). Associations were similar for stage II; for stage I only, bilateral mastectomy and chemotherapy were associated with continuation. Decision to continue did not vary by race, ethnicity, or demographic factors.
conclusionsNearly 40% of women with stage I breast cancer and two-thirds with stage II decided to extend endocrine therapy. Decision making was influenced by patient values and varied little by stage. These results can inform physician-patient discussion about extending endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.